Therapeutics for people with COVID-19 [ID4038], NICE

Draft guideline with the suggested remit: To appraise the clinical and cost effectiveness of remdesivir, tocilizumab, casirivimab and imdevimab, baricitinib, sotrovimab, molnupiravir, anakinra, lenzilumab and nirmatrelvir and ritonavir within their proposed marketing authorisations for treating people with symptomatic coronavirus disease 2019 (COVID-19).
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news